tert-butyl [2-(1H-tetrazol-2-yl)ethyl]carbamate | 1091611-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl [2-(1H-tetrazol-2-yl)ethyl]carbamate
• 英文别名: tert-butyl [2-(1H-tetrazol-1-yl)ethyl]carbamate；tert-butyl N-[2-(tetrazol-1-yl)ethyl]carbamate
• CAS: 1091611-51-6
• 化学式: C₈H₁₅N₅O₂
• 分子量: 213.239
• InChiKey: JLMMAALKIUPMPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(2H-Tetrazol-2-yl)ethanamine 、 2-(1H-tetrazol-1-yl)ethanamine 、 二碳酸二叔丁酯 以 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 生成 tert-butyl [2-(1H-tetrazol-2-yl)ethyl]carbamate 、 tert-butyl [2-(2H-tetrazol-2-yl)ethyl]carbamate
  参考文献：
  名称：

  [EN] 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
  [FR] 1,2,3-TRIAZINE-4-ONES 3-SUBSTITUÉES ET 1,3-PYRIMIDINONES 3-SUBSTITUÉES POUR AMÉLIORER LES RÉPONSES SYNAPTIQUES GLUTAMATERGIQUES

  摘要：

  公开号：

  WO2009038752A3

文献信息

• TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF
  申请人：Hisamichi Hiroyuki

  公开号：US20100227866A1

  公开（公告）日：2010-09-09

  [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

  [问题] 提供一种药物，特别是一种可用作治疗肠易激综合征（IBS）的治疗剂。 [解决问题的方法] 发现一种在4位具有酰胺基团或其药学上可接受的盐的四氢异喹啉-1-酮衍生物具有优异的肽释放因子2（BB2）受体拮抗作用。还发现四氢异喹啉-1-酮衍生物对肠道运动障碍非常有效。由此可见，本发明的四氢异喹啉-1-酮衍生物对与BB2受体相关的疾病，特别是IBS，具有治疗剂的用途。
• 3-SUBSTITUTED-1,2,3-TRIAZIN-4-ONE'S AND 3 SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
  申请人：Mueller Rudolf

  公开号：US20100267728A1

  公开（公告）日：2010-10-21

  This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

  本发明涉及化合物、药物组合物和方法，用于预防和治疗脑血液不足，包括增强大脑网络中负责基本和高级行为的突触中受体功能。这些大脑网络参与调节呼吸和认知能力，与记忆障碍相关，如多种痴呆症观察到的那样，以及在不同大脑区域之间的神经活动失衡中，如帕金森病、精神分裂症、呼吸抑制、睡眠呼吸暂停、注意力缺陷多动障碍和情感或情绪障碍中，以及神经营养因子缺乏有关的疾病，以及呼吸方面的疾病，如酒精、鸦片、阿片、巴比妥酸盐、麻醉剂或神经毒素过量，或呼吸抑制是由中枢性睡眠呼吸暂停、中风引起的中枢性睡眠呼吸暂停、阻塞性睡眠呼吸暂停、先天性低通气综合征、肥胖性低通气综合征、婴儿猝死综合征、雷特综合征、脊髓损伤、创伤性脑损伤、切尼-斯托克斯呼吸、温迪恩氏诅咒、普拉德-威利综合征和溺水等医学情况引起的。在特定方面，本发明涉及用于治疗此类疾病的化合物以及使用这些化合物进行此类治疗的方法。
• Tetrahydroisoquinolin-1-one derivative or salt thereof
  申请人：Seldar Pharma Inc.

  公开号：US10016410B2

  公开（公告）日：2018-07-10

  To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

  提供一种药物，特别是一种可用作肠易激综合征（IBS）治疗剂的化合物。研究发现，一种在 4 位具有酰胺基团的四氢异喹啉-1-酮衍生物或其药学上可接受的盐具有很好的蚕豆素 2（BB2）受体拮抗作用。研究还发现，四氢异喹啉-1-酮衍生物对肠道运动障碍也有很好的疗效。综上所述，本发明的四氢异喹啉-1-酮衍生物可作为一种治疗剂，用于治疗与 BB2 受体相关的疾病，特别是肠易激综合征。
• US8486970B2
  申请人：——

  公开号：US8486970B2

  公开（公告）日：2013-07-16
• US9150541B2
  申请人：——

  公开号：US9150541B2

  公开（公告）日：2015-10-06